Nicole Hamblin is Head of Small Molecule Drug Discovery within Discovery at Charles River. She holds a Chemistry degree and a PhD, both from Oxford University. Prior to joining Charles River in 2017, Nicole spent 20 years at GlaxoSmithKline as a medicinal chemist and cross discipline project leader, delivering multiple clinical candidates and leading the identification and progression of respiratory asset nemiralisib from hit ID into Phase IIb trials. Nicole has over 55 patents and peer-reviewed publications to her name, and in 2014 she won the Royal Society of Chemistry Capps Green Zomaya Award for medicinal chemistry. She was appointed a Fellow of the Royal Society of Chemistry in 2017 and currently sits on the RSC Organic Division Council and Medical Research Council grant review panels.
Small Molecule Drug Discovery is a cross-discipline team of over 200 talented scientists spanning Chemistry, Biology, DMPK, CADD, and Pharmaceutical Development, who are engaged in all aspects of drug discovery from hit identification to pre-clinical development. Working together as drug discovery experts, the team prides itself on scientific quality as evidenced by an impressive track record of over 90 pre-clinical candidates discovered for our partners. Alongside project work, the group strives to stay at the forefront of small molecule drug discovery, building capabilities and investing in new technologies in line with the latest developments in the field.
Publications
- Translation of inhaled drug optimization strategies into clinical pharmacokinetics and pharmacodynamics using GSK2292767A, a novel inhaled PI3Kδ inhibitor
- Developing Inhaled Drugs for Respiratory Diseases: A Medicinal Chemistry Perspective Drug Discov. Today, (2022), 27(1),134-150.
- Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma J. Med. Chem. (2020), 63(17), 10061-11085
- Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide-3 Kinase delta for the Treatment of Respiratory Disease Hamblin, J. Nicole Journal of Medicinal Chemistry (2015), 58, 7381−7399
- Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors Bioorganic & Medicinal Chemistry Letters (2008), 18(14), 4237-4241.